FY2029 Earnings Forecast for SLN Issued By HC Wainwright

Silence Therapeutics plc (NASDAQ:SLN) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Silence Therapeutics in a research note issued on Wednesday, January 29th. HC Wainwright analyst P. Trucchio expects that the company will earn $0.66 per share for the year. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.75) per share.

Several other research analysts have also recently issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research report on Tuesday, December 10th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $49.00 target price on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Silence Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $57.20.

Silence Therapeutics Stock Up 0.2 %

Shares of SLN opened at $5.25 on Friday. The firm has a market capitalization of $157.12 million, a PE ratio of -3.34 and a beta of 1.08. The firm has a 50-day moving average price of $6.63 and a 200 day moving average price of $13.94. Silence Therapeutics has a 52-week low of $4.82 and a 52-week high of $27.72.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds have recently modified their holdings of the stock. Eventide Asset Management LLC purchased a new stake in shares of Silence Therapeutics in the 3rd quarter valued at approximately $11,635,000. Millennium Management LLC lifted its holdings in shares of Silence Therapeutics by 91.2% in the second quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after purchasing an additional 373,523 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Silence Therapeutics by 219.3% in the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after purchasing an additional 321,300 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after buying an additional 268,250 shares during the period. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares in the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.